Showing results (201-210 of 253) with videos related to

Sort By:
Pageof 26
Clinical Pharmacology and Therapeutics|February 1, 2025
Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation StudyAmedeo De Nicolò, Alice Palermiti, Henry Mugerwa, et al.
Clinical Pharmacology and Therapeutics|June 2, 2019
Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated MalariaPalang Chotsiri, Lise Denoeud-Ndam, Elisabeth Baudin, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2022
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant TuberculosisLouvina E van der Laan, Anthony J Garcia-Prats, H Simon Schaaf, et al.
The Journal of Antimicrobial Chemotherapy|December 9, 2020
Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ARTHolly E Rawizza, Regina Oladokun, Emeka Ejeliogu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2022
Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant TuberculosisJennifer A Hughes, Belén P Solans, Heather R Draper, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2023
Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosisAli Mohamed Ali, Belén P Solans, Anneke C Hesseling, et al.
The Lancet. Child & Adolescent Health|November 23, 2020
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trialKatherine Gill, Leigh Johnson, Janan Dietrich, et al.
The Lancet. HIV|December 4, 2025
Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trialAnushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, et al.
Journal of the International AIDS Society|November 28, 2020
Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trialConnie L Celum, Katherine Gill, Jennifer F Morton, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2019
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years OldAnthony Enimil, Sampson Antwi, Hongmei Yang, et al.
Pageof 26